Assertio (US:ASRT) Globenewswire·2025-09-21 15:23Core Viewpoint - A New York federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to represent the class after the previous lead plaintiff was disqualified [1][4]. Group 1: Class Action Details - Investors who purchased Spectrum (SPPI) common shares during the Class Period (Mar. 17, 2022 – Sept. 22, 2022) and those who received shares of Assertio Holdings (ASRT) due to Assertio's acquisition of Spectrum may be eligible to represent the class [2][5]. - The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4]. Group 2: Legal Proceedings - The case has survived a motion to dismiss, and plaintiffs had moved for class certification, but proceedings were stayed due to allegations of misconduct by the court-appointed lead plaintiff [4]. - The new deadline for applying to be the lead plaintiff is September 24, 2025 [3]. Group 3: Hagens Berman's Role - Hagens Berman is actively investigating claims related to the case and encourages investors who suffered significant losses to consider becoming the new lead plaintiff [6]. - The firm has a history of representing investors and has secured over $2.9 billion in similar cases [7].